NCT01830205View on ClinicalTrials.gov

Pharmacokinetic and Safety Study of Daclatasvir in Patients With Renal Impairment

PHASE1CompletedINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

June 30, 2013

Study Completion Date

June 30, 2013

Conditions
Hepatitis C
Interventions
DRUG

Daclatasvir

Trial Locations (2)

32809

Orlando Clinical Research Center, Orlando

55404

Davita Clinical Research, Minneapolis

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT01830205 - Pharmacokinetic and Safety Study of Daclatasvir in Patients With Renal Impairment | Biotech Hunter | Biotech Hunter